Cabozantinib, a TKI targeting VEGFR2 and MET (a transmembrane tyrosine kinase receptor), decreased the proliferation and migration of osteosarcoma cells, and the production of RANK ligands via inhibition of the ERK and AKT signaling pathways (45). This evidence concerns the gene KDR and osteosarcoma.